

Tocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events

AER:		Local Case ID:	
Site No:		Patient Date of Birth (dd-MMM-yyyy):	
Patient ID/Initials:		Patient Gender:	M F
Patient Weight	🗌 kg 🗌 lb	Patient Height	🗌 cm 🔲 inch

Gastrointestinal perforations and related events have been observed in some patients treated with Tocilizumab.

By filling in this questionnaire, you will help us to understand more fully the risk factors for this condition.

Reporter Information		
Name of reporter completing this (if other than addressee, provide co		
Health Care Provider? Yes	No Specify:	
Phone Number:	Fax Number:	Email Address:

Reported Term

Description of the event	
Hospital Admission Yes (Admission Date MM/DD/YYYY):]No
(Discharge Date MM/DD/YYYY):	
Onset Date (MM/DD/YYY)	
Stop Date (MM/DD/YYY)	
Select all that apply:	
SERIOUSNESS CRITERIA CLASSIFICATION	
Death Date of Death (MM/DD/YYYY)	
Life-Threatening (use only if patient was at immediate risk of death due to event)	
Initial/Prolonged Hospitalization	
Congenital Anomaly/Birth Defect	
Persistent or Significant Disability	
Medically Significant (important medical events that may jeopardize the patient and may	require
/ersion 1.0, Effective Date: 18-June-2012	Page 1 of 5

medical/surgical intervention to pr	revent the other outcomes)	
Related to Tocilizumab?	Yes No	
Event led to surgery	Yes Please specify:	□No
Outcome of the event:	Persisting Improved Resolved Unknown Death	☐Recovered with sequelae ☐Worsened ☐

Drug therapy details – Tocilizumab					
Indication:					
Start Date (MM/DD/YYYY)					
Starting Dose	mg/	kg _	Total monthly dose (mg)		
Route					
Frequency	Monthly		Other, please specify:		
	Date (MM/DD/YYYY)	Dose	Action Taken in response to AE?		
			Dose maintained		
			Dose decreased		
			Dose interrupted		
			Dose increased		
			Dose discontinued		
			Dose maintained		
History of 4 most recent			Dose decreased		
Infusions prior to Adverse			Dose interrupted		
Event (AE)			Dose increased		
			Dose discontinued		
			Dose maintained		
			Dose decreased		
			Dose interrupted		
			Dose increased		
			Dose discontinued		
			Dose maintained		
			Dose decreased		
			Dose interrupted		
			Dose increased		
			Dose discontinued		

Treatment for the event					
What treatment was i	nitiated for the event? (incl	uding any pre-hospitalization treatment)			
Treatment	Dosing Regimen	Dates of Therapy (MM/DD/YYYY to MM/DD/YYYY)			

Version 1.0, Effective Date: 18-June-2012

Risk Factors

Please indicate if the following conditions are either part of the patient's medical history or are still active conditions.

Gastric ulcers	History		Not present
Specify:			
Duodenal ulcers	History		Not present
Specify:			
Inflammatory bowel disease	History		Not present
Specify:			
Diverticulosis	History		Not present
Specify:			
Diverticulitis	History		Not present
Specify:			
Gastrointestinal obstruction	History		Not present
Specify:			
Abdominal pain	History		Not present
Abdominal abscess	History		Not present
Fistula	History		Not present
Gastrointestinal bleeding	History		Not present
Specify:			
Cancer	History		Not present
Specify:			
Smoking	History		Not present
Alcohol abuse	History		Not present
Abdominal Surgery	History		Not present
Specify:			
Colonoscopy	History	Concurrent	Not present
Endoscopy	History	Concurrent	Not present
Other	History	Concurrent	Not present
Please Specify:			

Laboratory tests/ Imaging

Please provide SI (International System of Units) if available. Otherwise, as reported. Please attach all laboratory results and imaging tests. Labs Attached

Please indicate if any of the following tests have been performed, and the result:

Version 1.0, Effective Date: 18-June-2012

	Baseline Value (Prior to TCZ Use)	Date of Baseline Test (MM/DD/YYYY)	Date of Test (MM/DD/YYYY)	Test Results (include units)	Reference Range (If Applicable)	Pending?
CBC						□Yes
Laparoscopy						□Yes
Colonoscopy						Yes
Sigmoidoscopy						□Yes
EGD (Esophagogastro- duodenoscopy)						□Yes
CT Scan						□Yes
MRI						□Yes
Other						□Yes

Past/Concomitant Medications					
Medication List	Attached				
		Dose	Route	Frequency	Past, Concomitant, or N/A
Methotrexate	□Yes □ No				Past Concomitant N/A
Other DMARDs	□Yes				Past Concomitant N/A
Specify:	🗌 No				
Biologic DMARDs	Yes				Past Concomitant N/A
Specify:	🗌 No				
NSAIDs	Yes				Past Concomitant N/A
Specify:	🗌 No				
Corticosteroids	Yes				Past Concomitant N/A
Specify:	🗌 No				
PPIs	Yes				Past Concomitant N/A
Specify:	∐ No				
H2 blockers	Yes				Past Concomitant N/A
Specify:	∐ No				
Stool softeners	Yes				Past Concomitant N/A
Specify:	🗌 No				
Antibiotics	Yes				Past Concomitant N/A
Surgery	∐Yes □ No				Past Concomitant N/A
Other	Yes				Past Concomitant N/A
Please specify:	🗌 No				

Please provide any further relevant information about the Adverse Event.	Please indicate if
there have been any significant changes from the initial report.	

Thank you for completing this form.

Completed by	:	
Name:	Position:	
Signature:	Date:	
E-mail:		